ClinicalTrials.gg
Not yet recruitingNCT07939295KL002Updated Nov 16, 2026

Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study

A Phase 1/2 interventional study of Injecting KL002 into the bilateral putamen in Parkinson's Disease (PD) and Advanced Primary PD, sponsored by Kanglin Biotechnology (Hangzhou) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Kanglin Biotechnology (Hangzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 279 studies in Parkinson Disease with a site in China — 129 open to participants now, 136 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
174th of 211
12 · median 48
Started
2027
the only one that year
Phase 1/2
10 of 279
5 open now
Primary completion
2028-08
later than 116 of 135 live
Registered
279th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 174th largest by planned enrollment of the 211 interventional ones that give a count, is the only one that started in 2027, is one of 10 in phase 1/2, reaches primary completion later than 116 of the 135 other live ones, and was the 279th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

129 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

124 more — sign in →

All 129 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

Evaluate the safety and tolerability of stereotactic injection of KL002 into the putamen of patients with advanced primary PD.

Read the detailed description

This is an open-label, non-randomized, phase 1/2a single ascending dose study, consisting of Dose Escalation and Dose Expansion parts, to evaluate the safety, tolerability, and efficacy of KL002 in patients with advanced primary Parkinson's disease. Eligible subjects will enter the dose escalation part of the study, receive a single stereotactic intraputaminal administration of KL002, and be followed for 52 weeks in the core study and up to 5 years total in long-term follow-up (LTFU)with safety and efficacy assessments.

03

Conditions studied

  • Parkinson's Disease (PD)
  • Advanced Primary PD

Browse trials for

Keywords

  • Parkinson's Disease
  • gene therapy
  • KL002
  • AAV
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinically diagnosed primary PD
  2. Males or females ≥ 40 and ≤ 75 years old
  3. History of Parkinson's disease diagnosis ≥ 5 years
  4. Regularly take stable equivalent doses of dopaminergic drugs (including levodopa) for at least 4 weeks before the screening period
  5. Good compliance and regular follow-up

Exclusion criteria

Exclusion Criteria:

  1. Atypical or secondary Parkinson's syndrome
  2. Have surgical or have undergone brain surgery in the past
  3. Any indications of elevated intracranial pressure evaluated by investigator
  4. Abnormal liver and kidney function
  5. Prior severe allergic reactions or allergic to contrast agents or unable to accept surgical anesthesia
  6. Any type of prior gene or cell therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    low dose group

    Putamen stereotactic injection of low dose of KL002

    Genetic: Injecting KL002 into the bilateral putamen

  • Experimental
    high dose group

    Putamen stereotactic injection of high dose of KL002

    Genetic: Injecting KL002 into the bilateral putamen

Interventions

  • GeneticInjecting KL002 into the bilateral putamen

    KL002 is a recombinant adeno-associated virus (rAAV9) vector carrying TH, GCH1, and AADC genes

06

What researchers measure

Primary outcomes

  1. Adverse event (AE) incidence

    To evaluate AEs by CTCAE 6.0

    Time frame: From administration of KL002 to the end of the follow-up within 52 weeks

  2. The incidence rate of DLT events

    Determined by the Safety Data Review Committee

    Time frame: within 4 weeks

Secondary outcomes

  1. Assessment of motor function

    Determined by MDS-UPDRS III. The highest score is 56 points, and the lower the score, the better the recovery situation.

    Time frame: within 52 weeks

  2. Assessment of dyskinesia

    Determined by UDysRS. The highest score is 104 points, and the lower the score, the better the recovery situation.

    Time frame: within 52 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Aug 2028, 19 months later.

Of 55 phase 1/2 interventional studies under Parkinson Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Jan 2027
Primary completionEst.
Aug 2028
CompletionEst.
Oct 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939295
Lead sponsor
Kanglin Biotechnology (Hangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jan 2027 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Oct 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

jun Liu, Professor, Chief Physician, MD, Ph D
Contact
jly0520@hotmail.com
+86-021-64370045

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion